Foundation Medicine Launches Molecular Residual Disease (MRD) Test for Research Use in Early to Late-Stage Cancers Through its FlexOMx™ Lab

Foundation Medicine adds a tissue-informed whole genome sequencing molecular residual disease test to its portfolio of high-quality testing solutions.

Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive ...
Seeking Alpha

Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...
Targeted Oncology

Minimal Residual Disease Testing Gains Traction in CLL and Multiple Myeloma

Recent studies highlight the potential of minimal residual disease (MRD) testing to influence treatment decisions in multiple ...
Hosted on MSN

Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...
The American Journal of Managed Care

Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test

Flatiron Health and Exact Sciences collaborate to use Flatiron's platform for rapid data analysis with the Oncodetect MRD test. The study involves 1350 patients in community settings, focusing on ...
Nasdaq

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

Myriad Genetics, Inc. MYGN recently entered into a research partnership with National Cancer Center Hospital East ("NCCHE") in Japan to evaluate the prognostic and predictive value of molecular ...
Business Insider

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) ...
Seeking Alpha

Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth

CEO Christopher Hall reported Q1 2025 revenue of $20.6 million, marking a strong start to the year. He highlighted significant progress in their "Win-in-MRD" strategy, driven by demand for the company ...
Nasdaq

Myriad Genetics Reports Ultra-Sensitive CtDNA Detection With Precise MRD In Pan-Cancer Study

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...
NBC4 Columbus

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics

SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...
Hosted on MSN

The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.

A looming revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster biotech stocks like Guardant Health, Natera and Exact Sciences. And all it takes is a little blood.